Virobay Facts

2014 – Virobay announces the appointment of James Welch as Chief Financial Officer more

2014 – Virobay appoints Thomas J. Dietz, Ph.D. to the Virobay Board of Directors more

2013 – Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain more

2013 – Virobay and LEO Pharma initiate a Phase 1 Trial of VBY-891, a compound intended for oral treatment of psoriasis more

2012 – Virobay's Cathepsin S selected as one of the Top 10 Anti-Inflammatory/Autoimmune Projects to Watch more

2012 – LEO Pharma A/S has entered into a multi-million dollar collaboration with Virobay Inc. to develop an oral treatment for psoriasis more

2010 – Virobay closes Series B financing

more

Pipeline

Virobay is investigating promising new approaches for the treatment of neuroapathic pain, autoimmune diseases, liver fibrosis, and cancer.


Virobay Pipeline Table
 
Research
 
Phase 0
(Clinical Candidate)
 
Phase 1
 
Phase 2
VBY-891
Psoriasis - LEO Pharma     X  
VBY-036
Pain     X  
Autoimmunity     X  
VBY-376
Fibrosis/NASH     X  
VBY-825
Fibrosis/PBC   X    
VBY-285
Autoimmunity   X    
Multiple Candidates
Cancer, Alzheimer's X